CL2021000594A1 - Nuevos derivados de tiazol y sus sales farmacéuticamente aceptables - Google Patents

Nuevos derivados de tiazol y sus sales farmacéuticamente aceptables

Info

Publication number
CL2021000594A1
CL2021000594A1 CL2021000594A CL2021000594A CL2021000594A1 CL 2021000594 A1 CL2021000594 A1 CL 2021000594A1 CL 2021000594 A CL2021000594 A CL 2021000594A CL 2021000594 A CL2021000594 A CL 2021000594A CL 2021000594 A1 CL2021000594 A1 CL 2021000594A1
Authority
CL
Chile
Prior art keywords
pharmaceutically acceptable
acceptable salts
thiazole derivatives
new thiazole
new
Prior art date
Application number
CL2021000594A
Other languages
English (en)
Inventor
Kwang Ok Lee
Jakyung Yoo
Jun Hee Lee
Mijung Lee
Kangwoo Lee
Jieun Min
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CL2021000594A1 publication Critical patent/CL2021000594A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

El presente invento proporciona un nuevo derivado de tiazol o una sal farmacéuticamente aceptable de éste y un método para prepararlo. El derivado de tiazol o una sal farmacéuticamente aceptable de éste, de acuerdo con el presente invento, tiene una actividad inhibidora selectiva contra la quinasa dependiente de ciclina (CDK) y, por lo tanto, puede usarse de manera útil como un agente preventivo o terapéutico para diversas enfermedades asociadas con la CDK.
CL2021000594A 2018-09-17 2021-03-10 Nuevos derivados de tiazol y sus sales farmacéuticamente aceptables CL2021000594A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20180111001 2018-09-17

Publications (1)

Publication Number Publication Date
CL2021000594A1 true CL2021000594A1 (es) 2021-12-03

Family

ID=69887568

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000594A CL2021000594A1 (es) 2018-09-17 2021-03-10 Nuevos derivados de tiazol y sus sales farmacéuticamente aceptables

Country Status (19)

Country Link
US (1) US20210284658A1 (es)
EP (1) EP3853225B1 (es)
JP (1) JP7235859B2 (es)
KR (2) KR102130253B1 (es)
CN (1) CN112739695A (es)
AU (1) AU2019344240B2 (es)
BR (1) BR112021004999A2 (es)
CA (1) CA3106855A1 (es)
CL (1) CL2021000594A1 (es)
CO (1) CO2021003412A2 (es)
EA (1) EA202190558A1 (es)
IL (1) IL280639B (es)
MX (1) MX2021002456A (es)
PH (1) PH12021550572A1 (es)
SG (1) SG11202100531RA (es)
TW (1) TW202023548A (es)
UA (1) UA125427C2 (es)
WO (1) WO2020060112A1 (es)
ZA (1) ZA202101652B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102335637B1 (ko) * 2020-03-13 2021-12-06 영진약품 주식회사 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
JP2002518380A (ja) * 1998-06-18 2002-06-25 ブリストル−マイヤーズ スクイブ カンパニー サイクリン依存キナーゼの炭素置換アミノチアゾール抑制剤
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
IL159570A0 (en) * 2001-07-19 2004-06-01 Pharmacia Italia Spa Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
ES2313389T3 (es) * 2004-08-17 2009-03-01 F. Hoffmann-La Roche Ag Hidantoinas sustituidas.
US20090264415A2 (en) * 2004-12-30 2009-10-22 Steven De Jonghe Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
US8183239B2 (en) 2005-10-31 2012-05-22 Janssen Pharmaceutica Nv Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CA2686756A1 (en) 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
CA2742297A1 (en) * 2008-10-29 2010-05-20 Sirtris Pharmaceuticals, Inc. Pyridine, bicyclic pyridine and related analogs as sirtuin modulators
US9221773B2 (en) * 2009-12-22 2015-12-29 The Translational Genomics Research Institute Benzamide derivatives
US8952004B2 (en) * 2010-01-07 2015-02-10 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
US8404859B2 (en) 2011-03-16 2013-03-26 Hoffmann-La Roche Inc. Thiazole and thiophene compounds
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3057956B1 (en) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
EP2878339A1 (en) * 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
PT3126352T (pt) 2014-04-04 2018-12-27 Syros Pharmaceuticals Inc Inibidores da quinase dependente de ciclina 7 (cdk7)
CN113773257A (zh) * 2015-06-04 2021-12-10 奥瑞基尼探索技术有限公司 用作cdk抑制剂的经过取代的杂环衍生物

Also Published As

Publication number Publication date
CO2021003412A2 (es) 2021-04-08
EP3853225A1 (en) 2021-07-28
EA202190558A1 (ru) 2022-02-03
IL280639B (en) 2022-07-01
US20210284658A1 (en) 2021-09-16
SG11202100531RA (en) 2021-02-25
EP3853225B1 (en) 2023-11-29
AU2019344240A1 (en) 2021-02-25
JP2021535924A (ja) 2021-12-23
TW202023548A (zh) 2020-07-01
KR102130253B1 (ko) 2020-07-03
EP3853225C0 (en) 2023-11-29
IL280639A (en) 2021-03-25
UA125427C2 (uk) 2022-03-02
ZA202101652B (en) 2022-07-27
JP7235859B2 (ja) 2023-03-08
KR20200078465A (ko) 2020-07-01
WO2020060112A1 (en) 2020-03-26
BR112021004999A2 (pt) 2021-06-08
CA3106855A1 (en) 2020-03-26
KR20200032002A (ko) 2020-03-25
EP3853225A4 (en) 2022-06-15
PH12021550572A1 (en) 2021-10-25
CN112739695A (zh) 2021-04-30
MX2021002456A (es) 2021-06-15
AU2019344240B2 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
CO2019008487A2 (es) Compuesto de quinazolina
CL2019003086A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
ECSP18093777A (es) Derivados de pirazolopirimidina como inhibidor de quinasa
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
ECSP20035222A (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa
CR20160537A (es) Inhibidor de fosfoinosítido 3-quinasa delta para su uso medico
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
DOP2021000111A (es) 3,3- difluoroalilaminas o sales de las mismas y composiciones farmacéuticas que las comprenden
BR112018016729A2 (pt) novo composto de tiofeno substituído nas posições 2,3,5, utilizado como inibidor de proteína quinase
MX2017006224A (es) Derivados heterociclicos y usos de los mismos.
SV2016005313A (es) Derivados de carboxamida
DOP2012000058A (es) Agente terapeutico para trastornos del estado de animo
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
SV2017005354A (es) Derivados de quinolizinona como inhibidores de pi3k
CO2020000374A2 (es) Proceso mejorado para preparar derivados de aminopirimidina
CO2019012125A2 (es) Inhibidores ip6k
UY36123A (es) Derivados de carboxamida
CO2018001237A2 (es) Derivados de apramicina efectivos contra bacterias resistentes a múltiples fármacos y composiciones de los mismos
CO2021003412A2 (es) Nuevos derivados de tiazol y sus sales farmacéuticamente aceptables
CL2017002229A1 (es) Inhibidores de bace1.
CO2020000595A2 (es) Intermedios novedosos útiles para la síntesis de derivados de aminopirimidina, proceso para prepararlos, y proceso para preparar derivados de aminopirimidina usando estos
DOP2012000056A (es) Agente terapeutico para trastornos de ansiedad
CL2016002870A1 (es) Derivados bicíclicos y composición farmacéutica que incluye los mismos